NIAID Announces Funding For 12 Centers For AIDS Research

September 01, 1998

The National Institute of Allergy and Infectious Diseases (NIAID), along with five other NIH Institutes, has awarded more than $13 million for first-year funding for 12 Centers for AIDS Research (CFARs) across the United States.

The grants will provide three to five years of continued support for the Centers, which are based at leading AIDS research institutions around the country. CFARs provide a pool of shared resources - such as technical expertise, equipment and training - that is made available to local AIDS researchers. The Centers also advance AIDS research by facilitating interdisciplinary and international collaborations, technology transfer through academic-industry collaborations, research dissemination activities and promoting community outreach.

"HIV research requires expertise in multiple scientific fields and increasingly sophisticated procedures, so the integrated Center approach is an excellent way to achieve this goal," says NIAID Director Anthony S. Fauci, M.D.

First funded in 1988, the CFAR program has sponsored many exciting advances in AIDS research, including identification of new co-receptors for HIV, the role of cytotoxic T-lymphocytes in early infection and in controlling virus replication, and the use of antiretroviral drugs as probes to understand the dynamics of HIV replication. The program also has developed centralized research laboratories with state-of-the-art facilities and techniques, such as flow cytometry and DNA sequencing equipment, and made these available to all AIDS researchers in that community.

The CFARs also are committed to addressing concerns of minority communities, where AIDS is of particular concern. The Centers explore ways to increase the number of minority scientists involved in AIDS research and to deal with problems related to enrollment and retention of women and minorities in AIDS clinical trials.

A new feature of the awards is that they will be funded jointly by NIAID and five other NIH Institutes: the National Cancer Institute; the National Heart, Lung and Blood Institute; the National Institute of Child Health and Human Development; the National Institute on Drug Abuse; and the National Institute of Mental Health. For the first year, these institutes will contribute $7,030,000 and NIAID will pay $6,445,363, for a total of $13,475,362.

Of the twelve newly funded CFARs, six are renewals (indicated by asterisks below) and six are new grantees.

The awardees, with participating institutions and principal investigators, are:

ALABAMA
University of Alabama at Birmingham - Eric Hunter, Ph.D.*


CALIFORNIA
University of California at Los Angeles - Irvin Chen, M.D.*


University of California at San Diego with the Scripps Research Foundation, Burnham Cancer Research Foundation, and La Jolla Institute for Allergy and Immunology - Flossie Wong-Staal, M.D.*


University of California at San Francisco - Paul Volberding, M.D.*


GEORGIA
Emory University, Atlanta, with the AIDS Research Consortium of Atlanta, Yerkes Regional Primate Research Center and Atlanta VA Medical Center - James Curran, M.D., M.P.H.


ILLINOIS
Great Lakes CFAR, a collaboration of Northwestern University, Chicago, with the University of Minnesota, University of Wisconsin and University of Michigan - Steven Wolinsky, M.D.


MASSACHUSETTS
University of Massachusetts Medical Center - Mario Stevenson, Ph.D.


NEW YORK
Columbia and Rockefeller Universities, New York City, with the Aaron Diamond AIDS Research Center and the New York State Psychiatric Institute - David Ho, M.D.


NORTH CAROLINA
University of North Carolina, Chapel Hill, with Research Triangle Institute and Family Health International - Ronald Swanstrom, M.D.


OHIO
Case Western Reserve University, Cleveland - Stuart LeGrice, M.D.*


RHODE ISLAND
Miriam Hospital, Providence, with Brown University, Tufts University (Boston, Mass.), the New England Medical Center and Memorial Hospital of New England - Charles Carpenter, M.D.


WASHINGTON
University of Washington at Seattle with the Harbor View Medical Center and the Fred Hutchinson Cancer Research Center - King Holmes, M.D.*


These 12 newly funded sites are in addition to five ongoing CFARs at the following locations:

NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.
-end-
Press releases, fact sheets and other NIAID-related materials are available on the Internet via the NIAID web site at http://www.niaid.nih.gov.
-end-


NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.